Could The Market Be Wrong About Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Its Attractive Financial Prospects?

Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a rough month with its share price down 8.7%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals us

Simply Wall StJun 17 22:59

Catalyst Pharmaceuticals(CPRX.US) Officer Sells US$121.18K in Common Stock

$Catalyst Pharmaceuticals(CPRX.US)$ Officer Del Carmen Jeffrey sold 7,541 shares of common stock on Jun 7, 2024 at an average price of $16.07 for a total value of $121.18K.Source: Announcement What is

Futu NewsJun 12 05:43

Form 144 | Catalyst Pharmaceuticals(CPRX.US) Officer Proposes to Sell 121.18K in Common Stocks

SEC FILLINGS DISCLOSED/ Jun 7, $Catalyst Pharmaceuticals(CPRX.US)$ Officer Del Carmen Jeffrey intends to sell 7,541 shares of its common stock on Jun 7, with a total market value of approximately $121

Futu NewsJun 7 23:22

Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Been Rising: Are Strong Financials Guiding The Market?

Yahoo FinanceJun 7 23:16

Catalyst Pharmaceuticals Price Target Maintained With a $29.00/Share by Oppenheimer

Catalyst Pharmaceuticals Price Target Maintained With a $29.00/Share by Oppenheimer

Dow JonesJun 6 22:33

Express News | Reiterating its rating on Catalyst Pharmaceuticals (CPRX.US) from outperform to outperform and revising the target price from $29.00 to $29.00.

BreakingsJun 6 22:31